Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Johnson & Johnson’s Tremfya met key endpoints in the Phase 4 STAR trial in adults with psoriatic arthritis involving the spine. * Treatment significantly improved axial symptoms versus placebo, with MRI scans confirming reduced sacroiliac joint inflammation. * No new safety signals emerged; findings supported Tremfya’s established safety profile. * Late-breaking results are being presented at the Emirates Society for Rheumatology Annual Meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611200800PR_NEWS_USPR_____NY02933) on November 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.